Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids by Seitz, Christian et al.
Contemporary Clinical Trials 55 (2017) 56–62
Contents lists available at ScienceDirect
Contemporary Clinical Trials
j ourna l homepage: www.e lsev ie r .com/ locate /conc l int r ia lRationale and design of ASTEROID 2, a randomized, placebo- and active
comparator-controlled study to assess the efﬁcacy and safety
of vilaprisan in patients with uterine ﬁbroidsChristian Seitz a,⁎, Žana Bumbuliene b, Ana Rosa Costa c, Oskari Heikinheimo d, Andrea Heweker e,
Robert Hudeček f, Yves Jacquemyn g, Gian Benedetto Melis h, Pooja Parashar i, Tomasz Rechberger j,
Antonio Cano Sánchez k, Bart van Aken l, János Zatik m, Kristina Gemzell-Danielsson n
a Bayer AG, Development, Gynecologic Therapies, 13342 Berlin, Germany
b Vilnius University Faculty of Medicine, Clinic of Obstetrics and Gynaecology, Santariskiu str. 2, Vilnius LT-08406, Lithuania
c Serviço de Ginecologia e Obstetrícia, Hospital de São João, 4200-319 Porto, Portugal
d Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, PL 610, 00029 HUS, Finland
e Praxis für Gynäkologie und Geburtshilfe, Steinstrasse 6a, D-06406 Bernburg, Germany
f Department of Obstetrics and Gynecology, Faculty of Medicine, Masaryk University and University Hospital Brno, Obilní trh 11, 602 00 Brno, Czech Republic
g Department of Obstetrics and Gynaecology, UZA Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
h Dipartimento di Scienze Chirurgiche, Clinica Ostetrica e Ginecologica, Università di Cagliari, SS 554, Bivio Sestu, 09042 Monserrato, Cagliari, Italy
i Nesttun Spesialistpraksis, Østre Nesttunveien 14, 5221 Nesttun, Bergen, Norway
j Second Chair and Department of Gynaecology, Medical University of Lublin, ul. K. Jaczewskiego 8, 20-090 Lublin, Poland
k Hospital Clínico Universitario de Valencia, Av. de Blasco Ibáñez 15, 46010 València, Spain
l Flevoziekenhuis, Hospitaalweg 1, 1315 RA Almere, Netherlands
m Szent Anna Szuleszeti, Nogyogyaszati es Ultrahang Magan Rendelo, 48 Szent Anna utca, Debrecen, Hungary
n Department of Women's and Children's Health (KBH), K6, Karolinska Universitetssjukhuset Solna, H2:00, 17176 Stockholm, SwedenAbbreviations: AE, Adverse event; ASTEROID, Assess S
MRI, Magnetic resonance imaging; PAEC, Progesterone r
Patient Global Impression; PK, Pharmacokinetic; PRM, Pr
Uterine Fibroid Daily Symptom Diary; UFIS, Uterine Fibro
⁎ Corresponding author.
E-mail addresses: christian.seitz@bayer.com (C. Seitz)
(O. Heikinheimo), a.heweker@t-online.de (A. Heweker), r
ipooja1329@gmail.com (P. Parashar), rechbergt@yahoo.co
kristina.gemzell@ki.se (K. Gemzell-Danielsson).
http://dx.doi.org/10.1016/j.cct.2017.02.002
1551-7144/© 2017 Bayer AG. Published by Elsevier Inc. Ta b s t r a c ta r t i c l e i n f oArticle history:
Received 5 September 2016
Received in revised form 2 February 2017
Accepted 4 February 2017
Available online 6 February 2017Background: Uterine ﬁbroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have
been shown to reduce heavymenstrual bleeding and the size of UFs. To date, one PRM (ulipristal acetate) has re-
ceived regulatory approval for the treatment of UFs; therapy comprises intermittent treatment courses of up to
3months each, followed by a break to allow twomenstruations to occur.We report the design of ASTEROID (As-
sess Safety and efﬁcacy of vilaprisan in patients with uTERine ﬁbrOIDs) 2, a phase 2 study examining the efﬁcacy
and safety of a novel PRM, vilaprisan, in women with UFs.
Methods/design: In this randomized multi-arm study, vilaprisan (2 mg daily) will be administered in different
regimens: continuous treatment for 12 or 24 weeks, or two 12-week treatment periods separated by a break
to allow one menstruation to occur. Efﬁcacy and safety will be compared with that of ulipristal acetate (5 mg
daily) and placebo. Patients randomized to receive placebo for 12 weeks will also be given active treatment for
12 weeks. The primary measure of efﬁcacy will be amenorrhoea rate; secondary measures include time to nor-
malized menstrual bleeding and percentage change in UF volume. Endometrial changes will be monitored
throughout the study.
Discussion: The placebo- and active comparator-controlled trial ASTEROID 2 is the ﬁrst study to evaluate system-
atically the efﬁcacy and safety of different treatment regimens of PRMs in women with UFs. The ﬁndings of this
study will direct the planning of future clinical trials of vilaprisan.
© 2017 Bayer AG. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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57C. Seitz et al. / Contemporary Clinical Trials 55 (2017) 56–621. IntroductionUterine ﬁbroids (UFs) are the most common benign tumours in
women. Findings from ultrasound screening of more than 1000 ran-
domly selected members of an urban health plan suggest that 70–80%
of women will develop UFs during their lifetime [1]. Although many
womenwill remain asymptomatic, the presence of UFs can cause symp-
toms including heavy menstrual bleeding (HMB), pelvic pressure and
pain [2], which have a signiﬁcant impact on women's quality of life
[3]. Many women undergo invasive procedures, including hysterecto-
my, to treat the symptoms of UFs [4]. In a study of medical records
from aUK primary care database, nearly a quarter ofwomen underwent
hysterectomy or invasive procedures such as myomectomy or uterine
artery embolization within 1 year of diagnosis of UFs [5]. Medical ther-
apy for the long-term treatment of UFs would reduce the need for inva-
sive procedures, which are associated with signiﬁcant morbidity [6].
Progesterone receptormodulators (PRMs) act directly on progester-
one receptors in the smoothmuscle of UFs, resulting in inhibition of cell
proliferation and stimulation of apoptosis [7,8]. In women with UFs,
treatment with PRMs such as mifepristone, asoprisnil and ulipristal ac-
etate (UPA) has been shown to induce amenorrhoea [9–13]; further-
more, UPA has been shown to reduce UF size to a similar extent as
uterine artery embolization [14]. UPA (5 mg daily) is approved in the
European Union for the intermittent treatment of moderate to severe
symptoms of UFs in adult women of reproductive age [15]. Treatment
with PRMs is known to induce benign histological changes of the endo-
metrium known as progesterone receptor modulator associated endo-
metrial changes (PAECs) [16]. In phase 3 clinical trials of UPA in
women with UFs, the duration of treatment was initially limited to
3 months [10,11]. Recently, the efﬁcacy and safety of up to four 3-
month treatment courses of UPA have been evaluated in women with
UFs; each treatment periodwas separated by a break to allow twomen-
struations to occur [17–19]. However, patients reported some return of
symptoms (HMB and pain) and a corresponding reduction in quality of
life during the treatment breaks [17,18]. The efﬁcacy and safety of alter-
native UPA treatment regimens (for example, continuous treatment for
6 months) have not been evaluated.
Vilaprisan (VPR) is a novel PRM with a ﬁvefold higher anti-
progestagenic potency than UPA [20]. In a phase 1 study [21], treatment
with VPR resulted in a dose-dependent reduction of menstrual
bleeding in healthy volunteers. Observed non-bleeding rates (self-
assessed intensity of menstrual bleeding as ‘none’ or ‘spotting’)
reached more than 90% among women taking a 2 mg daily dose of
VPR for 3 months [21]. Here, we report the design of ASTEROID (As-
sess Safety and efﬁcacy of vilaprisan in patients with uTERine ﬁ-
brOIDs) 2 (ClinicalTrials.gov identiﬁer NCT02465814; EudraCT
number 2014-004221-41). This phase 2 study is the ﬁrst to evaluate
systematically the efﬁcacy and safety of different treatment regi-
mens of PRMs in patients with UFs.Fig. 1. Design of the ASTEROID 2 (Assess Safety and efﬁcacy2. Methods/design
2.1. Study objectives
The primary objective of ASTEROID 2 is to assess the efﬁcacy of VPR
(12 and 24 weeks of treatment) compared with placebo (12 weeks) in
patients with UFs. The safety of VPR and the efﬁcacy of different VPR
treatment regimens in comparison with UPA will be evaluated as sec-
ondary objectives. Further aims are to supplement data on the popula-
tion pharmacokinetic (PK)/pharmacodynamic (PD) relationship for
VPR in patients with UFs.2.2. Study design
ASTEROID 2 is a multi-arm, randomized, parallel-group, phase 2
study of female patients with UFs, which is being carried out at approx-
imately 70 centres in 16 European countries. The study comprises three
main treatment groups (A, B and C)with a total of seven treatment arms
(Fig. 1). All three groups of patients will take part in two 12-week treat-
ment periods during the study. Patients randomized to groups A and B
will receive VPR (2 mg once daily) or daily placebo tablets followed by
VPR (2mg once daily). Those in group C will receive the active compar-
ator UPA (5 mg once daily), placebo followed by UPA, or UPA followed
by placebo. Treatment period 1 will commence within 3 days of the
start of the ﬁrst menstruation following randomization.
For patients in group A, treatment periods 1 and 2 will run continu-
ouslywithout a break.Womenwill receiveVPR for 24weeks (treatment
arm A1) or placebo for 12 weeks followed by VPR for 12 weeks (treat-
ment arm A2). Women in group B will receive two 12-week courses
of VPR (treatment arm B1) or placebo followed by VPR (treatment
arm B2). For this group of patients, there will be a break at the end of
treatment period 1 until menstruation occurs. Treatment period 2 will
commence within 3 days of the start of menstruation. Women in
group C will receive two 12-week courses of UPA (treatment arm C1),
placebo followed by UPA (treatment arm C2) or UPA followed by place-
bo (treatment arm C3). All patients in group C will have a break at the
end of treatment period 1 that will be long enough to allow two men-
struations to occur. Treatment period 2 will commence within 3 days
of the start of the secondmenstruation that occurs during the treatment
break. This reﬂects the approved treatment regimen for UPA. For all
groups A, B and C, a 12-week follow-up phase will commence at the
end of treatment period 2.
All aspects of the study design and protocol have been approved and
reviewed by the Institutional Review Board of each participating centre.
The study will be conducted in compliance with the principles detailed
in theDeclaration ofHelsinki and in accordancewithGood Clinical Prac-
tice guidelines.Written informed consentwill have been provided by all
participants.of vilaprisan in patients with uTERine ﬁbrOIDs 2) study.
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Patient eligibility for ASTEROID 2 will be conﬁrmed during the
screening period that will last for up to 60 days prior to randomization.
Key inclusion and exclusion criteria are shown in Table 1. Women aged
18–50 yearsmust have a diagnosis of UFs, documented by abdominal or
transvaginal ultrasound (TVU). Eligible patients must have at least one
UFwith a largest diameter of ≥3 cm, andmust experience HMB, deﬁned
as more than 80 mL of blood loss per menstrual cycle (measured by
menstrual pictogram [MP]), that must occur within 10 days during the
screening period. The MP employs a visual scoring system to document
and assessmenstrual ﬂuid loss for each sanitary product (towels and/or
tampons) that a patient uses [22,23].2.4. Randomization and blinding
Eligible patients will be randomized in a blockwisemanner, without
stratiﬁcation, to one of seven treatment arms as shown in Fig. 1. Owing
to differences in the treatment regimens it will not be possible to
achieve blinding between groups A, B and C. However, double blinding
will be established between treatment arms A1 and A2, B1 and B2, and
C1, C2 and C3. Therefore, patients and study investigators will be aware
of the treatment group assignment, but will have no knowledge of the
treatment arm allocation. To maintain blinding, VPR or UPA and their
respective placebo tablets will be identical in appearance. Patients and
investigators will be unblinded in the event of a suspected, unexpected
serious adverse reaction.Table 1
Key inclusion and exclusion criteria for the ASTEROID 2 study.
Key inclusion criteria
• Women aged 18–50 years at screening
• Diagnosis of uterine ﬁbroids documented by transvaginal or abdominal ultra-
sound at screening, with at least one uterine ﬁbroid with a largest
diameter ≥ 3 cm
• HMB (N80 mL within 10 consecutive days) during the screening period as
measured by menstrual pictogram
• Normal or clinically insigniﬁcant ﬁndings in cervical smear (Pap test)
• No signiﬁcant endometrial pathology as determined by endometrial biopsy
during the screening period
• Use of non-hormonal (barrier) contraceptive for the duration of the study
Key exclusion criteria
• Pregnancy or lactation less than 3 months before the start of treatment
• Uterine ﬁbroid with a largest diameter N 10 cm
• Haemoglobin levels ≤ 60 g/L or any condition requiring blood transfusion
• Any condition or medication that may interfere with the conduct of the study
or interpretation of the results, including:
o severe coagulation disorders or anaemia unrelated to HMB
o history of or current gynaecological cancer (including any ovarian tumours or
pelvic masses of unclear aetiology that require further investigation)
o endometrial ablation or uterine artery embolization b 6 months prior to
screening
o one or more ovarian cysts ≥ 3 cm in diameter, as measured by ultrasound
o known or suspected uterine polyp N 1.5 cm
o prior use of short-acting hormonal contraceptives (oral, vaginal or transder-
mal), contraceptive devices with or without hormone release (implant, intra-
uterine device), tranexamic acid or other treatments for HMB, if not stopped or
removed before the start of the menstrual cycle following screening visit 1
o prior use of injectable hormonal contraceptives, if last application was per-
formed less than one application interval before the start of the menstrual
cycle following screening visit 1
o prior use of gonadotropin-releasing hormone agonists, if not stopped at least
one application interval before the start of the screening period;
o previous use of ulipristal acetate without satisfactory treatment response
o anticoagulants taken within the last 2 weeks prior to ﬁrst study drug intake
and during the treatment period
• Undiagnosed abnormal genital bleeding
ASTEROID, Assess Safety and efﬁcacy of vilaprisan in patientswith uTERine ﬁbrOIDs; HMB,
heavy menstrual bleeding.2.5. Efﬁcacy measures
The primary efﬁcacy variable is amenorrhoea, which is deﬁned as no
menstrual bleeding or spotting from the end of the last menstrual bleed
(at the start of the respective treatment period) throughout the remain-
der of the treatment period (Table 2). If an endometrial biopsywas con-
ducted during the treatment period, any bleeding on the day of biopsy
or during the 3 days thereafter will not be considered in this evaluation.
Other measures of efﬁcacy that will be evaluated as secondary end-
points are outlined in Table 2.
2.6. Study procedures
The procedures to be carried out during study visits are outlined in
Table 3. To assess HMB, patients will be asked to rate any menstrual
bleeding within the past 24 h on a daily basis using the following cate-
gories: no bleeding, spotting, mild, moderate, severe and very severe.
These data will be recorded electronically using the Uterine Fibroid
Daily Symptom Diary (UF-DSD) [24]. A bleeding episode constitutes
any days on which bleeding is recorded as mild, moderate, severe or
very severe that are preceded and followed by at least 2 bleed-free days.
Tomeasure the volume of UFs and of the uterus, pelvicmagnetic res-
onance imaging (MRI) will be performed within 7 days of the time
points outlined in Table 3. Images of diagnostic quality will be acquired
using high-resolutionMRI (1.5 Tesla or higher) without contrast agents.
Volume measurements will be performed by two independent radiolo-
gists who will be blinded to treatment allocation. TVU or abdominal ul-
trasound (depending on UF location) will be performed to measure the
transverse, longitudinal and antero-posterior diameters of the three
largest UFs at the time points outlined in Table 3. The type of examina-
tion, the machine to be used and the investigator performing each ex-
amination will be consistent for each patient throughout the study.
Patient-reported outcomes (PROs) and treatment administration
will be recorded using an electronic diary (eDiary) and tablet comput-
er-based questionnaires. The PROmeasures to be included in the eDiaryTable 2
Key efﬁcacy endpoints for the ASTEROID 2 study.
Primary efﬁcacy endpoint
• Amenorrhoea (yes/no), deﬁned as no menstrual bleeding or spotting for the
duration of the TP (except for the menstrual bleed at the start of the respective
TP and any bleeding on the day of endometrial biopsy or within the 3 days
thereafter)
Secondary efﬁcacy endpoints
• Number of bleeding days per 28 days, from day 1 of the ﬁrst TP until the day
before the next TP would start
• Time to onset of normalized bleeding, deﬁned as the ﬁrst day for which the
menstrual blood loss (assessed by MP) for all subsequent 28-day cycles up to
the end of the TP is less than 80 mL
• Change in volume (%) of largest uterine ﬁbroid compared with baseline, mea-
sured by MRI
Further efﬁcacy endpoints
• Volume of menstrual blood loss per 28 days (assessed by MP) and during the
ﬁrst, second and third menstrual cycles after the end of treatment visit
• Proportion of patients with 50% reduction in menstrual bleeding per 28 days
(assessed by MP) compared with baseline
• Time to onset of amenorrhoea, deﬁned as the ﬁrst day for which the menstrual
blood loss is less than 2 mL for all subsequent 28-day cycles up to the end of
the TP, as measured by MP
• Time to start of bleeding after last study drug/placebo intake. If bleeding has to
be induced, the patient's data will be censored at the time of induction
• Change in volume of the largest uterine ﬁbroid and of the uterus (% change
compared with baseline), measured by both ultrasound and MRI
• Proportion of patients undergoing surgical treatment
• Change in patient-reported outcome and ClinRO questionnaire scores and
assessments compared with baseline
ASTEROID, Assess Safety and efﬁcacy of vilaprisan in patients with uTERine ﬁbrOIDs
ClinRO, clinician reported outcome; MP, menstrual pictogram; MRI, magnetic resonance
imaging; TP, treatment period.
Table 3
Schedule of procedures for the ASTEROID 2 study.
Period
Screening TP1
B
TP2
Follow-up
Visit 1 2 3 4 5 6 7 8 9 10
Timing (weeks following start of TP1 or TP2) +4 +8 +12 +4 +8 +12 8–12 weeks after EOT
Informed consent X
Inclusion/exclusion criteria X (X) X
Demographics, smoking status, alcohol consumption, medical history X
Physical examination X X X X
Vital signs, body weight, height X X X X X
Gynaecological examination including breast palpation X X X
Urine pregnancy test X X X X X X X X X X
Cervical smear X X
Ultrasound examination X X X X X X X X X X
Endometrial biopsy X X X
MRI X X X X
Safety, laboratory and urinalysis X X X X X X X
Additional laboratory parameters X X X X
Blood sample for PK X X X X
PROs (eDiary)
UF-DSD including bleeding diary ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔
Menstrual pictogram ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔
UFIS ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔ ➔
PROs (tablet computer)
UFS-QoL X X X X X
SF-36v2 X X X X X
PGI-S X X X X X X X X X
PGI-C X X
ClinRO (RAVE)
CGI-S X X X X X X X X X
CGI-C X X
Ongoing data collection (daily questionnaire); (X), check of eDiary entries via the web. ASTEROID, Assess Safety and efﬁcacy of vilaprisan in patients with uTERine ﬁbrOIDs; B, treatment
break; CGI-C, Clinician Global Impression of Change; CGI-S, Clinician Global Impression of Severity; ClinRO, clinician-reported outcome; EOT, end of treatment; MRI, magnetic resonance
imaging; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity; PK, pharmacokinetics; PROs, patient-reported outcomes; RAVE, electronic data captur-
ing system; SF-36v2, 36-item Short-FormHealth Survey Version 2; TP, treatment period; UF-DSD, Uterine Fibroid Daily SymptomDiary; UFIS, Uterine Fibroid Impact Scale; UFS-QoL, Uter-
ine Fibroid Symptom and Quality of Life questionnaire.
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UF-DSD will be used to document the severity of UF symptoms such as
pain, swelling and bloating. The impact of these symptoms on daily ac-
tivities, for example the ability to carry, lift, walk and stand, will be doc-
umented using the UFIS. The severity of vaginal bleeding will be
assessed using the daily bleeding diary and the MP. The tablet comput-
er-based questionnaires include theUterine Fibroid SymptomandQual-
ity of Life questionnaire (UFS-QoL), the 36-item Short-Form Health
Survey Version 2, the Patient Global Impression (PGI) of Change and
the PGI of Severity. Thesewill be used to assess the impact of symptoms
on various aspects of quality of life such as mood, self-consciousness,
sexual function, and mental and emotional health.
2.7. Pharmacokinetics/pharmacodynamics
Plasma VPR and UPA concentrations will be determined using a val-
idated liquid chromatography–mass spectrometry/mass spectrometry
method. For analysing plasma VPR concentrations, blood samples will
be taken at the time points outlined in Table 3. At the end of the
study, the PK of VPR will be analysed using non-linear mixed effect
models to describe the relationship between dose, time and plasma
drug concentration. A population PK/PDmodel will be developed to de-
scribe the relationship between exposure and PD effects such as bleed-
ing intensity. Plasma UPA concentrations will be compared with
published data in order to assess treatment compliance.
2.8. Safety
Frequent visits to the study site are planned for safety monitoring
(Table 3). Endometrial safety assessments will includemonthly TVU in-
vestigations, analysis of bleeding patterns and endometrial biopsies.
During TVU investigations, endometrial thickness will be measured
and the ovaries will be evaluated. If follicle-like structures greater than3 cm in diameter are observed, further TVU examinationswill be carried
out to monitor outcomes.
Patients will undergo three scheduled endometrial biopsies during
the study. The ﬁrst biopsy will be performed during the screening peri-
od, followed by a second biopsy after the end of treatment period 2 and
a third during the follow-up phase (approximately 8 weeks after the
end of treatment period 2). All biopsies will be performed on day 9 ±
2 of themenstrual cycle that occurs at the speciﬁed time point. If the en-
dometrial thickness is found to be greater than 18mm, or if a patient has
been experiencing suspicious bleeding patterns, an unscheduled endo-
metrial biopsy will be performed. If hyperplasia is detected, the study
treatment will be stopped immediately and diagnostic sampling of the
endometrium (such as curettage) may be considered. In the absence
of these ﬁndings, patients will continue to take study medication and
will undergo additionalmonitoring of endometrial thickness and bleed-
ing patterns.
If amenorrhoea persists for up to 10weeks after treatment cessation
(either at the end of treatment period 1 or at the end of the study), pa-
tientswill undergo additional unscheduled TVU and endometrial biopsy
to check for endometrial changes. Menstruation will be induced by use
of a progestin such as oral norethisterone acetate 2.5–10 mg daily for
10 days. Any patient who requires a progestin after treatment period
1 will not be entered into treatment period 2.
Laboratory safety tests include themeasurement of hormones (such
as follicle-stimulating hormone, progesterone, cortisol and thyroxine-
binding globulin) and bonemarkers, serum chemistry, urinalysis, coag-
ulation status and haematology proﬁle. For patients with haemoglobin
levels of 109 g/L or below, iron supplementation will be offered in a
standard regimen. The occurrence of adverse events (AEs) will also be
monitored.
A non-hormonal contraceptive method must be used from the be-
ginning of treatment period 1 (i.e. at the start of menstruation following
the screening visit) until the end of the study. However, regular
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tended pregnancies will be closely monitored. Any pregnancy that oc-
curs during the treatment or follow-up periods will be monitored in
terms of outcomes for both mother and fetus/child, and, in the case of
live births, until the child's ﬁrst birthday. Any abnormal outcomes for
mother or child will be reported as serious AEs.2.9. Statistical analysis
The study populations that will be used for analysis of efﬁcacy are
the full analysis set, which will include all randomized patients who
took at least one dose of study drug or placebo, and the per protocol
set, which will include all patients in the full analysis set without any
major protocol deviations. Protocol deviations include treatment, time
schedule and procedure deviations, randomization errors and with-
drawal criteria, and will be deﬁned and assessed as major or minor be-
fore data are unblinded.
For primary efﬁcacy analysis, the amenorrhoea rates with VPR
(12 weeks of treatment and 24 weeks of treatment) and placebo
(12 weeks) will be compared (Table 4). The null hypothesis that the
proportion of patients with amenorrhoea in the vilaprisan group is
equal to the proportion of patients with amenorrhoea in the placebo
group, against the alternative hypothesis that they are not equal, will
be tested at two time points (12 weeks and 24weeks). Two hypotheses
(Supplementary Table 1) will therefore be tested sequentially using a
hierarchical (ﬁxed sequence) testing procedure on a signiﬁcance level
of 5% (two-sided Fisher's exact test). The application of the ﬁxed se-
quence testing approach means that an adjustment for multiplicity is
not necessary. Missing data in the patient eDiaries will be imputed:
the bleeding intensity for the missed day(s) will be assumed to be
equivalent to the maximum intensity recorded on the day before or
day after the missing day(s).
The secondary efﬁcacy variables (Table 2) will be analysed descrip-
tively; no hypothesis testingwill be performed. To compare the efﬁcacy
of VPR with that of UPA, the amenorrhoea rate and number of bleeding
days (both with two-sided 95% conﬁdence intervals) will be compared.
The treatment arms to be included in each analysis are outlined in Table
4.
Safety analyses will be performed on the safety analysis set, which
will include all patients who took at least one dose of study drug or pla-
cebo. Each AEwill be assigned to treatmentwith VPR, UPA or placebo. If
the AE occurs when a patient is taking placebo after a treatment period
with an active drug, the AE will be assigned to the active drug. The inci-
dence of treatment-emergent AEs and drug-related AEswill be summa-
rized using the Medical Dictionary for Regulatory Activities preferred
terms.
Statistical analyses will be performed using Statistical Analysis Soft-
ware (SAS Institute Inc., Cary, NC, USA). Datawill be presented using de-
scriptive statistics such as frequency or mean and standard deviation.Table 4
Findings from different treatment arms of ASTEROID 2 that will be pooled to conduct the
primary and secondary efﬁcacy analyses.
Primary efﬁcacy analysis (amenorrhea rate):
• VPR at 12 weeks (treatment arm A1, n = 30) vs placebo at 12 weeks (treatment
arms A2, B2 and C2 pooled, n = 18)
• VPR at 24 weeks (treatment arm A1, n = 30) vs placebo at 12 weeks (treat-
ment arms A2, B2 and C2 pooled, n = 18)
Secondary efﬁcacy analysis (amenorrhea rate and number of bleeding days):
• VPR at 12 weeks (treatment arms A1 and B1 pooled, n = 60)
• UPA at 12 weeks (treatment arms C1 and C3 pooled, n = 60)
• VPR at 24 weeks with no treatment break (treatment arm A1, n = 30)
• VPR at 24 weeks including treatment break (treatment arm B1, n = 30)
• UPA at 24 weeks including treatment break (treatment arm C1, n = 30)
ASTEROID, Assess Safety and efﬁcacy of vilaprisan in patients with uTERine ﬁbrOIDs; UPA,
ulipristal acetate; VPR, vilaprisan.Individual changes from baseline to the end of treatment will be
analysed if appropriate.
2.10. Determination of sample size
Sample size calculations are based on the primary endpoint,
amenorrhoea rate with VPR compared with placebo, and were per-
formed using Power Analysis and Sample Size (PASS) 11 software
(NCSS Statistical Software, Kaysville, UT, USA). An allocation ratio of
5:1 for each active treatment arm to its respective placebo arm was ap-
plied. Data from previous studies [11,21] were used to estimate the an-
ticipated size of effect. Details of the calculations used for the primary
and secondary efﬁcacy analyses are shown in Supplementary Tables 2
and 3, respectively. Based on an expected amenorrhoea rate of 80%
with VPR and 5% with placebo at a two-sided 5% signiﬁcance level, 25
patients in the VPR arm and 5 in each of the three placebo arms
would result in a power of at least 95%. Patients will not switch treat-
ment arm and any patients who drop out of the study will not be re-
placed: an overall dropout rate of 17% is anticipated and is a
conservative estimate based on previous experience in studies with
similar populations and complexity (unpublished data). Therefore,
138 patients in total will be recruited – 30 in each active treatment
arm and 6 in each placebo arm. Data from patients randomized to re-
ceive placebo for treatment period 1 will be pooled for the primary efﬁ-
cacy analysis (Table 4).
Secondary efﬁcacy analyses will be reported in terms of descriptive
statistics with two-sided 95% conﬁdence intervals, calculated using the
Clopper–Pearsonmethod, as outlined in Supplementary Table 3. The in-
clusion of treatment arm C3 will allow at least 50 patients taking UPA
(25 each from treatment arms C1 and C3), in addition to the 50 patients
taking VPR (treatment arms A1 and B1), to be included in the secondary
efﬁcacy analysis (Supplementary Table 3).
3. Discussion
ASTEROID 2 is a randomized, placebo- and active comparator-con-
trolled study with multiple treatment arms that is designed to evaluate
the efﬁcacy and safety of different treatment regimens of VPR, a novel
PRM. Different regimens of VPR (2 mg daily) will be compared: contin-
uous treatment for 12 or 24weeks, and 12-week treatment periods sep-
arated by a break to allow one menstruation to occur. The active
comparator UPA will be administered in the regimen that has received
regulatory approval for the treatment of UFs: 12-week treatment pe-
riods separated by a break to allow two menstruations to occur [15].
PRMs can display effects ranging from antagonist to mixed antagonist/
agonist actions at the progesterone receptor and pharmacological activ-
ity can be difﬁcult to predict from in vitro data alone [25]. The most ap-
propriate regimen for the treatment of UFs should be investigated for
each PRM, and may not necessarily be the same for all members of
this class of agents. ASTEROID 2 is the ﬁrst study to asses systematically
the effects of different treatment regimens of PRMs in womenwith UFs.
The use of PRMs is associatedwith the development of benign histo-
logical changes of the endometrium, termed PAECs [16], which are re-
versible upon treatment cessation and menstruation [10,11,17–19,26].
In the PEARL (PGL4001 Efﬁcacy Assessment in Reduction of symptoms
due to uterine Leiomyomata) phase 3 clinical studies of UPA, 62% of
women taking UPA 5 mg daily for 12 weeks developed PAECs, com-
pared with 6% of those taking placebo [10]. In a study of the contracep-
tive effects of UPA delivered continuously via an intravaginal ring for
24 weeks, the proportion of healthy volunteers found to have PAECs
was 78.8% [26]. In contrast, PAECs were observed in 38.5% of patients
with UFswho received the PRMmifepristone (5mg daily) for 9 months
[9]. Taken together, these data suggest that endometrial ﬁndings may
differ depending on the PRM being studied, as well as the duration of
treatment [16], and highlight the importance of establishing agent-spe-
ciﬁc treatment regimens for patients with UFs.
61C. Seitz et al. / Contemporary Clinical Trials 55 (2017) 56–62The frequency, duration and intensity ofmenstrual bleeding are sub-
ject to variability in response to factors such as physical and emotional
stress, which can result in amenorrhoea [27]. The comparison of VPR
with placebo in ASTEROID 2 is therefore required in order to distinguish
treatment effects from the natural variability of menstruation and the
inﬂuence of factors unrelated to treatment. Furthermore, there has
only been one previous study comparing the active comparator, UPA,
with placebo [10]. In the absence of established assay sensitivity, a com-
parison of VPR with UPA alone would be associated with a risk of
overestimating the treatment effect of VPR [28]. The inclusion of place-
bo in ASTEROID 2 will establish assay sensitivity and internal validity of
the trial [28]. However, from an ethical perspective, it is important that
the number of patients treatedwith placebo isminimized because alter-
native options for the treatment of UFs already exist; if left untreated,
the symptoms of UFs can have a considerable negative impact on pa-
tients' quality of life. Therefore, an imbalanced randomization approach
(5:1 active:placebo) has been incorporated into the design of ASTEROID
2, and data from the placebo treatment arms will be pooled to enhance
statistical power. Moreover, all patients who are randomized to receive
placebo will then also be given active treatment for at least 12 weeks in
treatment period 2. The comparison of VPR with UPA will provide fur-
ther validation of the study ﬁndings, a recognized beneﬁt of a multi-
arm clinical trial design [29]. Furthermore, ﬁndings from treatment
arm C3 (UPA 5mg daily for 12 weeks followed by daily placebo tablets)
will be comparedwith those frompatients receiving VPR (2mgdaily for
12 weeks) in ASTEROID 1 (ClinicalTrials.gov identiﬁer NCT02131662),
which is assessing the efﬁcacy and safety of different doses of VPR in
women with UFs for 12 weeks.
In the PEARL phase 3 studies, once daily dosing of UPA 5 mg for
12 weeks resulted in amenorrhoea in 73–75% of patients [10,11]. The
deﬁnition of amenorrhoea was a score of 2 or less on the 28-day picto-
rial blood loss assessment chart (PBAC). However, thismeasure has lim-
itations because the PBACmethod [30] was developed and validated for
use with sanitary products that were no longer available at the time of
the PEARL studies. In ASTEROID 1 and 2, HMB will be assessed using
the MP, which has been validated for use with modern sanitary wear
[22,23].
The ﬁndings of several studies suggest that the prevalence of UFs
may be higher in women of African origin than in Caucasian women
[1,31]. However, no women of African origin were recruited in PEARL
I, and this population made up less than 10% of the patients in PEARL
II [32]. ASTEROID 2 is being carried out at over 70 centres in Europe,
where the active comparator, UPA, is currently approved for the inter-
mittent treatment of UFs [15]. The ethnic diversity of the European pop-
ulation is likely to be reﬂected in the study population enrolled into
ASTEROID 2. In addition, the population to be studied in ASTEROID 1
will includewomen from theUSA and Japan. Taken together, the results
of these studies are expected to provide further insight into the efﬁcacy
of VPR in women of diverse ethnic backgrounds, including those of Afri-
can descent.
In summary, ASTEROID2 is amulti-arm, placebo and active-compar-
ator study that will assess the efﬁcacy and safety of VPR. This is the ﬁrst
study to assess systematically the efﬁcacy and safety of different treat-
ment regimens of PRMs. Data are expected to be available in 2017.
The ﬁndings of ASTEROID 2 will direct the planning of future studies
of VPR in women with UFs.
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